Ampulla of Vater Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma arising from the ampulla of Vater. The vast majority of cases are adenocarcinomas. Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss. 
Ampulla of vater carcinomas most frequently harbor alterations in TP53, KRAS, APC, CDKN2A, and ARID2 .
TP53 Mutation, KRAS Mutation (somatic), KRAS Mutation (germline), KRAS Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in ampulla of vater carcinoma .
There are 4 clinical trials for ampulla of vater carcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain ampulla of vater carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open).
ERBB2 and UGT1A1 are the most frequent gene inclusion criteria for ampulla of vater carcinoma clinical trials .
Flucytosine, oncolytic vaccinia virus tg6002, and irinotecan are the most common interventions in ampulla of vater carcinoma clinical trials.
Significant Genes in Ampulla of Vater Carcinoma
ERBB2 is mutated in 8.82% of ampulla of vater carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Irinotecan and trastuzumab are the most frequent therapies in ampulla of vater carcinoma trials with ERBB2 mutations as inclusion criteria .
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains UGT1A1 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.